Literature DB >> 1790159

Brain gamma-aminobutyrate transaminase and monoamine oxidase activities in suicide victims.

F Sherif1, J Marcusson, L Oreland.   

Abstract

The activity of gamma-aminobutyrate amino-transferase (GABA-T) and monoamine oxidase (MAO-A and -B) was measured in 42 postmortem human brains. Three brain regions (frontal cortex, cingulate cortex and hypothalamus) from 23 controls without known neurological or psychiatric disorder and from 19 suicide victims were analysed. The suicide victims were classified according to the use of violent and non-violent methods and to the presence or absence of a known history of depressive disorder. No difference was found between the series of suicide victims and the control subjects with regard to GABA-T activity. Carbon monoxide poisoning and death by drug overdose, however, were found to reduce the activity. The MAO-B activity did not differ between the groups. With MAO-A, however, a significant elevation (t = 2.01; P less than 0.05) was found in the hypothalamic region of the suicide victims. The difference seemed to be confined to the subgroup of suicides with a record of depressive disorder.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1790159     DOI: 10.1007/bf02219712

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  47 in total

1.  Inhibitors of GABA metabolism: implications for Huntington's disease.

Authors:  R Schwarcz; J P Bennett; J T Coyle
Journal:  Ann Neurol       Date:  1977-10       Impact factor: 10.422

2.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

3.  Reduced central serotonin turnover in a subgroup of alcoholics?

Authors:  A Roy; M Virkkunen; M Linnoila
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1987       Impact factor: 5.067

4.  GABA-transaminase activity in rat and human brain: regional, age and sex-related differences.

Authors:  F Sherif; L Eriksson; L Oreland
Journal:  J Neural Transm Gen Sect       Date:  1991

5.  Schizophrenia, tardive dyskinesia, and brain GABA.

Authors:  T L Perry; S Hansen; K Jones
Journal:  Biol Psychiatry       Date:  1989-01-15       Impact factor: 13.382

6.  The effect of vigabatrin on brain and platelet GABA-transaminase activities.

Authors:  J B Bolton; E Rimmer; J Williams; A Richens
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

7.  Suicide attempts, platelet monoamine oxidase and the average evoked response.

Authors:  M S Buchsbaum; R J Haier; D L Murphy
Journal:  Acta Psychiatr Scand       Date:  1977-07       Impact factor: 6.392

8.  GABA levels in CSF of patients with psychiatric disorders.

Authors:  B I Gold; M B Bowers; R H Roth; D W Sweeney
Journal:  Am J Psychiatry       Date:  1980-03       Impact factor: 18.112

9.  Brain GABAA/benzodiazepine binding sites and glutamic acid decarboxylase activity in depressed suicide victims.

Authors:  S C Cheetham; M R Crompton; C L Katona; S J Parker; R W Horton
Journal:  Brain Res       Date:  1988-09-13       Impact factor: 3.252

10.  Tritiated imipramine binding sites are decreased in the frontal cortex of suicides.

Authors:  M Stanley; J Virgilio; S Gershon
Journal:  Science       Date:  1982-06-18       Impact factor: 47.728

View more
  9 in total

1.  The reduction of R1, a novel repressor protein for monoamine oxidase A, in major depressive disorder.

Authors:  Shakevia Johnson; Craig A Stockmeier; Jeffrey H Meyer; Mark C Austin; Paul R Albert; Junming Wang; Warren L May; Grazyna Rajkowska; James C Overholser; George Jurjus; Lesa Dieter; Chandra Johnson; Donald B Sittman; Xiao-Ming Ou
Journal:  Neuropsychopharmacology       Date:  2011-06-08       Impact factor: 7.853

2.  Brain monoaminergic and neuropeptidergic variations in human aging.

Authors:  B Arranz; K Blennow; R Ekman; A Eriksson; J E Månsson; J Marcusson
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Evidence revealing deregulation of the KLF11-MAO A pathway in association with chronic stress and depressive disorders.

Authors:  Sharonda Harris; Shakevia Johnson; Jeremy W Duncan; Chinelo Udemgba; Jeffrey H Meyer; Paul R Albert; Gwen Lomberk; Raul Urrutia; Xiao-Ming Ou; Craig A Stockmeier; Jun Ming Wang
Journal:  Neuropsychopharmacology       Date:  2014-12-15       Impact factor: 7.853

4.  Pharmacoepigenetics of depression: no major influence of MAO-A DNA methylation on treatment response.

Authors:  Katharina Domschke; Nicola Tidow; Kathrin Schwarte; Christiane Ziegler; Klaus-Peter Lesch; Jürgen Deckert; Volker Arolt; Peter Zwanzger; Bernhard T Baune
Journal:  J Neural Transm (Vienna)       Date:  2014-05-10       Impact factor: 3.575

5.  Neither single-marker nor haplotype analyses support an association between monoamine oxidase A gene and bipolar disorder.

Authors:  San-Yuan Huang; Ming-Teng Lin; Mee-Jen Shy; Wei-Wen Lin; Fang-Yi Lin; Ru-Band Lu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-04-24       Impact factor: 5.270

6.  5-HT2C receptor and MAO-A interaction analysis: no association with suicidal behaviour in bipolar patients.

Authors:  Vincenzo De Luca; Subi Tharmaligam; John Strauss; James L Kennedy
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-05-26       Impact factor: 5.270

7.  Association of the MAOA promoter uVNTR polymorphism with suicide attempts in patients with major depressive disorder.

Authors:  For-Wey Lung; Dong-Sheng Tzeng; Mei-Feng Huang; Ming-Been Lee
Journal:  BMC Med Genet       Date:  2011-05-24       Impact factor: 2.103

Review 8.  Molecular Targets of Cannabinoids Associated with Depression.

Authors:  Pradeep Paudel; Samir Ross; Xing-Cong Li
Journal:  Curr Med Chem       Date:  2022       Impact factor: 4.740

Review 9.  The role of the serotonergic system in suicidal behavior.

Authors:  Marta Sadkowski; Brittany Dennis; Robert C Clayden; Wala Elsheikh; Sumathy Rangarajan; Jane Dejesus; Zainab Samaan
Journal:  Neuropsychiatr Dis Treat       Date:  2013-11-06       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.